NCT06018428Phase 2Active not recruiting

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-06Estimated

Enrollment · participants75Estimated

Source updated2026-05-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-31 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Alopecia Areata

Treatments or interventions studied

bempikibart (ADX-914)Drug

Primary outcomes · main study measures

measure: Part A: Mean relative percent change in SALT score; description: Part A: Mean relative percent change in SALT score at 24 weeks compared with baseline; timeFrame: 24 Weeks; measure: Part B: Mean percent change from baseline in SALT score; description: Part B: Mean percent change from baseline in SALT score at Week 36; timeFrame: 36 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history